Biochemix
IV Infusion Manufacturing Company in India
To protect large-volume parenterals from human touch and environmental particles, a world-class IV Infusion manufacturing company in india must deploy sophisticated automation.
Years in Manufacturing
Brand Partners
Product SKUs
Batch Pass Rate
Introduction: The Growing Need for Precision in IV Manufacturing
India’s healthcare system is scaling faster than ever before. As hospitals expand their critical care infrastructure and pharma brands race to meet clinical demand, the need for a dependable IV infusion manufacturing company in India has moved from preference to business necessity. Intravenous fluids are the backbone of modern hospital medicine — they deliver life-saving hydration, correct electrolyte imbalances, support nutrition, and carry critical medications directly into the bloodstream. These healthcare infusion solutions support millions of critically ill patients every single day. Consequently, the quality of every IV bag directly impacts patient outcomes, making the choice of the right intravenous infusion manufacturer one of the most consequential decisions a pharma brand can make.
Biochemix Healthcare Pvt. Ltd., headquartered in Yamunanagar, Haryana, has stepped up to meet this demand with authority. As a dedicated infusion solution manufacturer with over 17 years of specialized experience in sterile parenteral manufacturing, 500+ product SKUs, and a WHO-GMP and DCGI-certified facility, Biochemix delivers intravenous therapy products that pharma brands, PCD distributors, and hospital procurement teams trust without reservation. This article explores in depth why Biochemix leads the field as the most complete and compliant IV infusion manufacturing partner available in India today.
Who Is Biochemix Healthcare Pvt. Ltd.?
Biochemix Healthcare Pvt. Ltd. is a premier contract development and manufacturing organization (CDMO) and WHO-GMP infusion manufacturer established in 2009. Located at Vill. Kotarkhana, Jagadhri, Yamunanagar — a rapidly emerging pharmaceutical cluster in North India — the company operates a state-of-the-art IV fluid manufacturing company infrastructure that accommodates six distinct injectable dosage platforms under one roof.
As a fully certified IV infusion manufacturing company in India, Biochemix holds active regulatory approvals from some of the most respected bodies in global pharma:
- WHO-GMP — World Health Organization Good Manufacturing Practice certification
- DCGI — Drugs Controller General of India approval
- NABL — National Accreditation Board for Testing and Calibration Laboratories
- ISO 9001:2015 — International Quality Management System certification
Additionally, the company manufactures all products to IP (Indian Pharmacopoeia), BP (British Pharmacopoeia), and USP (United States Pharmacopoeia) standards, making its product range eligible for both the domestic market and export to regulated and semi-regulated international territories.
Key performance metrics that define Biochemix’s operational excellence:
- 17+ years in sterile parenteral manufacturing
- 500+ product SKUs across therapeutic segments
- 200+ pharma partners across PAN-India and export markets
- 98% first-pass batch release rate — a benchmark few facilities in India match
Six Injectable Platforms, One Facility: Comprehensive Manufacturing Capabilities
Large Volume Parenterals (LVP) — The Core Strength
Biochemix’s primary strength as an IV infusion manufacturing company in India and leading large volume parenteral manufacturer lies in its robust LVP manufacturing infrastructure. The company produces sterile infusion products in ISO-validated aseptic filling lines with terminal steam sterilization technology. Every infusion bottle undergoes 100% integrity testing before leaving the facility — establishing Biochemix as a trusted infusion bottle manufacturer with zero compromise on container closure integrity. Moreover, continuous particle monitoring in Grade A environments ensures that each batch complies with pharmacopoeial limits for particulate matter and bacterial endotoxins.
The LVP range covers the complete spectrum of intravenous therapy products for critical and general care settings:
- Normal Saline (0.9% NaCl) — Biochemix operates as a dedicated IV saline manufacturer, supplying this essential fluid for hydration and electrolyte correction across hospitals in India
- Ringer’s Lactate Solution — for surgical and trauma fluid management
- Dextrose solutions (5%, 10%, 25%, 50%) — as a certified dextrose infusion manufacturer, Biochemix supplies a full range of glucose supplementation fluids to ICUs and general wards
- Dextrose Normal Saline combinations — for mixed electrolyte therapy
- Sodium Bicarbonate (7.5% and 8.4%) including the newly launched SODAZOX-8.4%
- Mannitol infusions — for cerebral edema and renal protection
- Amino acid and nutritional parenteral solutions — for ICU nutritional support
Small Volume Parenterals (SVP)
Beyond large volume infusions, Biochemix fills ampoules and vials ranging from 1 mL to 50 mL in Grade A laminar airflow environments. Automated glass welding and hermetic capping processes protect product integrity throughout the cold chain. The SVP range includes antibiotics, anti-fungals, hormones, and specialty injectables that hospitals and surgical centers rely on daily.
Lyophilized Injectables
For temperature-sensitive biologics, protein-based drugs, and oncology formulations, Biochemix operates dedicated lyophilization (freeze-drying) production lines. Lyophilized powder-for-injection products offer enhanced shelf stability and longer shelf life — critical advantages for high-value injectable molecules that cannot tolerate aqueous conditions.
Cytotoxic and Oncology Injectables
Biochemix maintains fully segregated negative-pressure suites for the safe production of cytotoxic drugs and chemotherapy formulations. Strict personnel protection protocols, closed-system transfer devices, and independent HVAC systems ensure that workers, the environment, and the product all remain uncompromised throughout the process.
Dry Powder Injectables
Aseptic filling of sterile dry powder antibiotics and anti-fungal agents takes place in Grade A environments under nitrogen atmosphere purge — eliminating oxidation risk and maintaining API potency through the product’s entire shelf life.
Ophthalmic Preparations
The facility also houses a dedicated sterile ophthalmic manufacturing line operating at Grade A with 0.22 µm filtration, preservative-free formulation options, and sealed LDPE delivery systems — meeting the growing demand from ophthalmic surgeons and hospital pharmacies across India.
Quality Systems That Set the Industry Benchmark
What truly elevates Biochemix above competitors as a preferred IV infusion manufacturing company in India is the depth and discipline of its quality assurance and quality control infrastructure. Every batch of pharmaceutical infusion products that leaves the facility passes through a multi-layer testing protocol — covering analytical, microbiological, and physical characterization — ensuring that the sterile infusion products Biochemix delivers consistently meet global pharmacopoeial standards.
The in-house NABL-accredited laboratory performs comprehensive analytical testing on every batch, including:
- LAL Endotoxin Testing using both kinetic turbidimetric and gel-clot methods per IP/USP specifications
- Membrane filtration sterility testing as per Indian Pharmacopoeia 2022 requirements
- 100% automated visual inspection combined with semi-automated particulate matter analysis
- Certificate of Analysis (CoA) generation covering all pharmacopoeial parameters before batch release
Moreover, the manufacturing environment itself maintains Grade A/B cleanroom standards — ISO Class 5 filling zones within ISO Class 7 background environments — with continuous viable and non-viable particle monitoring through validated environmental monitoring programs. Pyrogen-free borosilicate containers and fully segregated packaging lines add an additional layer of product protection.
Biochemix also follows ICH-compliant accelerated and real-time stability protocols. As a result, pharma partners receive full dossier support for new product filings and regulatory variations — reducing time-to-market and eliminating compliance bottlenecks.
A Manufacturing Process Designed for Reproducibility
Biochemix operates a rigorous five-stage workflow that transforms every new formulation from concept into a commercially released product:
Stage 1 — Formulation Review: API compatibility profiling, excipient evaluation, and pharmacopoeial alignment before raw materials enter the production area.
Stage 2 — Raw Material QC: Incoming testing, CoA verification, and approved vendor qualification ensure only compliant inputs are used.
Stage 3 — Aseptic Filling: Grade A fill-finish in validated suites with media fill qualification executes the core manufacturing step under contamination-controlled conditions.
Stage 4 — Sterilization: Terminal steam sterilization, ETO, or 0.22 µm filtration sterilization is applied based on the specific product specification.
Stage 5 — QC Batch Release: Full analytical testing, sterility confirmation, endotoxin verification, and authorized quality person sign-off complete the cycle before product dispatch.
This structured, reproducible workflow directly produces Biochemix’s 98% first-pass batch release rate — a number that reflects genuine process discipline rather than post-production rework.
New Product Launches That Keep Your Portfolio Competitive
Biochemix continuously expands its range of pharmaceutical infusion products and injectable formulations to address emerging therapeutic needs. Recent new launches include Extmin DS, Bioday-RD Kit, CITZEP-1000, DEXOFEEL, PERONEM-TZ 1125, RANTIWEL-50, Ropa-XT, Sheeni-200, SODAZOX-8.4%, and WIN-HCG-5000 — spanning anti-infectives, critical care fluids, and specialty injectables.
Furthermore, the company’s formulation development team actively works with partner brands to co-develop new molecules, line extensions, and combination products — transforming Biochemix from a passive manufacturer into a true strategic product development partner.
Why Pharma Brands Choose Biochemix: The Complete Picture
When pharma brands search for the best IV infusion manufacturers in India, they need more than just a production facility — they need a consistent, accountable IV fluid supplier in India who brings quality, compliance, and genuine collaboration to every relationship. As you evaluate your options, here is why Biochemix consistently ranks as the most recommended IV infusion manufacturing company in India among established and emerging pharmaceutical brands:
| Parameter | Biochemix Performance |
|---|---|
| Years of Experience | 17+ Years in Sterile Parenterals |
| Regulatory Certifications | WHO-GMP, DCGI, NABL, ISO 9001:2015 |
| Manufacturing Platforms | LVP, SVP, Lyophilized, Cytotoxic, Dry Powder, Ophthalmic |
| Cleanroom Standards | Grade A (ISO Class 5) in Grade B (ISO Class 7) |
| Product SKUs | 500+ across therapeutic segments |
| Pharma Partners | 200+ across India and export markets |
| Batch Pass Rate | 98% First-Pass QC Compliance |
| Lab Accreditation | NABL-Certified In-House QC Lab |
| Dossier Support | ICH-Compliant Stability + Full Filing Assistance |
Additionally, Biochemix’s transparent communication, consistent quality track record, and responsive business development team have earned long-term loyalty from partners — some of whom have been working with the company for over 17 years.
Conclusion: Your Next Injectable Partnership Starts Here
India’s critical care pharmaceutical market demands manufacturers who combine precision engineering, deep regulatory knowledge, and genuine partnership values. Biochemix Healthcare Pvt. Ltd. delivers on every dimension — which is why it stands as the most strategically complete and operationally proven IV infusion manufacturing company in India for pharma brands that refuse to compromise on quality, compliance, or consistency.
Testimonials
Sterile. Compliant. Scalable.
Ready to Bring Your Next Batch to Market?
Take the next step. Connect with Biochemix today and discover how we can build your injectable portfolio together.